Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-101 for acute inner ear tinnitus
NL-OMON33296Phase 2Active, not recruiting
- Sponsor
- Altamira Therapeutics
- Start
- Feb 2010
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Keyzilen in tinnitus (3 arms), sponsored by Altamira Therapeutics. Primary endpoint: Change in minimum masking level. Started Feb 2010; status: active, not recruiting.
02
Drugs
Keyzilen
03
Conditions
tinnitus
Beyond the preview
Go deeper on NL-OMON33296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33296.